We're glad to announce that Chiesi Group’s internal Center of open innovation and competence (COI&C), “The Impulse”, will join FH24 as a sponsor with their platform.

Chiesi Group is an international biopharmaceutical group focused on research, with over 85 years of experience. Its headquarters are located in Parma, Italy, and Chiesi exports to more than 100 countries, with a direct presence in 31. The Group researches, develops, and delivers innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. In 2018, Chiesi amended its by-laws to become a Benefit Corporation, formally committing to creating shared value for society as a core, legally binding objective integrated into all company decision-making processes.. In 2019, Chiesi obtained the B Corp certification, which was reconfirmed in 2022 after a thorough assessment of its internal processes.

“The Impulse” is Chiesi’s newest open innovation platform, designed to drive impactful change in healthcare. “The Impulse” embraces partnerships that tackle today’s biggest challenges—whether in digital health, patient care, or sustainability. By addressing not only symptoms but the root causes of healthcare issues, such as climate change and access to care, “The Impulse” seeks out a new generation of healthcare solutions. With a strong focus on collaboration, it offers a unique space for innovators, researchers, and start-ups to experiment and bring new ideas to life. At its core, “The Impulse” envisions a future where technology and health converge for the benefit of all, focusing on human-centric solutions that not only transform patient outcomes but also consider their broader impact on society and the environment.

Discover more about Chiesi's Center of Open Innovation & Competence (COI&C) and their platform, The Impulse, at FH24. Get your pass now.